Bioleaders Corporation (142760) — Cash Flow Reinvestment Rate

Latest as of September 2024: 76.60x

Bioleaders Corporation (142760) has a Cash Flow Reinvestment Rate of 76.60x as of September 2024, reinvesting ₩3.80 Billion (capex ₩1.04 Billion plus investments ₩2.75 Billion) from operating cash flow of ₩49.56 Million. Check Bioleaders Corporation cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

76.60x
(Capex + Investments) / Operating CF

Total Reinvested

₩3.80 Billion
Capex + Investments

Operating Cash Flow

₩49.56 Million
KRW

Capital Expenditures

₩1.04 Billion
KRW

Bioleaders Corporation Cash Flow Reinvestment Rate (2023–2023)

Historical reinvestment intensity for Bioleaders Corporation across 1 annual periods. Explore Bioleaders Corporation long-term investment allocation to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Bioleaders Corporation (2023–2023)

Year-by-year capital reinvestment analysis for Bioleaders Corporation. For live market cap and broader valuation context, see 142760 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (KRW) Operating CF Capex YoY Change
2023 5.01x ₩30.93 Billion ₩6.18 Billion ₩378.81 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow